Merck KGaA of Germany (XETRA:MRK.DE) has received approval from the Japanese Ministry of Health, Labour and Welfare for Juniper Pharmaceuticals’ (NASDAQ:JNP) OneCrinone 90 mg (progesterone) for the indication of luteal phase supplementation in assisted reproductive treatment.
“This approval further expands the global Crinone progesterone gel franchise into the world’s’ third largest pharmaceutical market, giving women and couples struggling with infertility in Japan a new, patient-friendly therapeutic option for luteal phase support,” Frank Condella, CEO of Juniper, said in a statement. “We look forward to supporting the launch of OneCrinone in Japan later this year.”
Merck KGaA has worldwide marketing rights to Crinone except in the U.S., where it is marketed by Allergan (NYSE:AGN).
